To Congress, From Pharma: Love, Hate And Fresh Ideas For 21st Century Cures
Industry and key stakeholders weigh in on House Commerce Committee’s first take at biomedical reform; brand companies offer lots of positive feedback but want many modifications; generic companies criticize multitude of new exclusivity provisions for brands.
You may also be interested in...
Amendment defunding Planned Parenthood is one ACA repeal refugee that could hitch a ride with user fee bill, which would be 'problematic,' to say the least, for Democrats.
Providing a transferable period of patent-life extension in exchange for US FDA approval of a new antibiotic would incentivize ‘the whole ecosystem’ to find new treatments for emerging diseases, CEO Ian Read says.
Advisory committee unanimously votes against bardoxolone for Alport syndrome, unconvinced drug slows progression of chronic kidney disease and concerned about safety signals suggesting it could make the disease worse. However, panel offers Reata suggestions for a better-designed trial.